-
公开(公告)号:US11903980B2
公开(公告)日:2024-02-20
申请号:US18050091
申请日:2022-10-27
申请人: KoBioLabs, Inc.
发明人: Gwangpyo Ko , Boram Seo , Woon Ki Kim , Kyungchan Jeon
IPC分类号: A61K35/741 , A61K39/02 , A61K35/00 , A23L33/135 , A61K39/00
CPC分类号: A61K35/741 , A23L33/135 , A61K39/0208 , A23V2002/00 , A61K2035/115 , A61K2039/542
摘要: The present invention relates to a microorganism which can act as a biomarker of alcoholic fatty liver disease, and relates to a pharmaceutical composition for preventing or treating alcoholic fatty liver disease, a food composition for preventing or improving alcoholic fatty liver disease, or a probiotics composition for preventing or improving alcoholic fatty liver disease, comprising the strain as an active ingredient.
-
公开(公告)号:US11602552B2
公开(公告)日:2023-03-14
申请号:US16962976
申请日:2019-02-07
申请人: KoBioLabs, Inc.
发明人: Yongbin Choi , Jisoo Kim , June-Chui Lee , Gwang Pyo Ko , Tae-Wook Nam , Jun-Hyeong Kim , Bo-Ram Cho
IPC分类号: A61K35/747 , A23K10/18 , A23L33/135
摘要: The present invention relates to a composition comprising at least one selected from the group consisting of a novel lactic acid bacterium, Lactobacillus plantarum KBL396 (KCTC13278BP), culture of the strain, lysate of the strain and extract of the strain, and its use for food and medicine. The strain and composition according to the present invention has an excellent effect on improvement of neurological diseases, particularly improvement of mental disorders and neurodegenerative diseases, and has no risk of side effects in a human body, and thus it can be usefully utilized as a use for improvement of neurological diseases.
-
公开(公告)号:US20220002665A1
公开(公告)日:2022-01-06
申请号:US17279247
申请日:2019-10-11
申请人: KoBioLabs, Inc.
发明人: Gwang Pyo KO , Hyo Shin YOON , Chung Hwan CHO , Hyun Ju YOU , Tae Wook NAM
摘要: The present invention relates to Akkermansia muciniphila SNUG-61027 strain (accession number KCTC 13530BP) and use thereof, specifically, a composition for suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases, comprising the strain, or a culture solution thereof, etc. or a B2UM07 protein isolated therefrom as an active ingredient, and use thereof for suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases, and a method of suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases using the same are provided. Through this, among the anti-obesity effects, not only weight reduction and glucose homeostasis regulation, but also the effect on brown fat and the effect of secreting appetite regulating hormones are exhibited.
-
公开(公告)号:US20190264262A1
公开(公告)日:2019-08-29
申请号:US16316662
申请日:2017-07-20
发明人: GwangPyo KO , Jiyeon SI , Cheonghoon LEE
摘要: The present invention relates to markers being capable of predicting or diagnosing the risk of metabolic syndrome or metabolic syndrome-related diseases and their use. More particularly, the present invention relates to a composition, a kit and a method for predicting or diagnosing the risk of metabolic syndrome or metabolic syndrome-related diseases by detecting Neisseria spp., Granulicatella spp., and/or Peptococcus spp. in a test sample.
-
公开(公告)号:US11992511B2
公开(公告)日:2024-05-28
申请号:US17673460
申请日:2022-02-16
申请人: KoBioLabs, Inc.
发明人: Gwang Pyo Ko , Woonki Kim , You-Jin Jang , Boram Seo , June-Chul Lee , Tae-Wook Nam , Insu Kim , Jin-Woo Lee
IPC分类号: A61K35/747 , A23L33/00 , A23L33/135 , A61P1/00 , A61P37/08 , C12N1/20 , A61K35/00 , C12R1/225
CPC分类号: A61K35/747 , A23L33/135 , A23L33/40 , A61P1/00 , A61P37/08 , C12N1/20 , C12N1/205 , A23V2002/00 , A23V2400/165 , A61K2035/115 , C12R2001/225
摘要: Human-derived probiotic strains Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384 and Lactobacillus paracasei KBL385 are described, as well as uses of the strains for improving intestinal health and treating or preventing intestinal diseases. The strains have excellent anti-inflammatory and immunomodulatory functions, superb strengthening effects on tight junctions of the intestinal tract wall, suppress enteritis-induced weight loss and colon length reduction, thereby exhibiting therapeutic effects for enteritis, and significantly alleviate the symptoms of atopic dermatitis. The strains can be used as probiotic material for enhancing anti-inflammatory effects, strengthening immunity, improving intestinal health functions, and alleviating allergic diseases.
-
公开(公告)号:US20230173019A1
公开(公告)日:2023-06-08
申请号:US17996956
申请日:2021-04-21
申请人: KoBioLabs, Inc.
发明人: Inseong Jo , Sung Hyun Moon , Bo-Ram Cho , Tae-Wook Nam
IPC分类号: A61K38/16 , A61P3/00 , C07K14/195
CPC分类号: A61K38/16 , A61P3/00 , C07K14/195 , C12N15/70
摘要: This disclosure relates to a protein variant having improved GLP-1 inducibility and/or thermal stability and enzyme resistance, and a pharmaceutical composition for reducing body weight and/or body fat, suppressing appetite or treating or preventing of metabolic diseases, comprising the same.
-
公开(公告)号:US20230046756A1
公开(公告)日:2023-02-16
申请号:US17765972
申请日:2020-09-29
申请人: KoBioLabs, Inc.
发明人: Tae Wook Nam , Kiuk Lee , Seok Cheon Song , Seung Hyeok Han , Bo Young Nam , Ji Min Park
IPC分类号: C12N1/20 , A23L33/135 , A23K10/16 , A61K35/747 , A61P13/12
摘要: The present invention relates to a Lactobacillus acidophilus KBL409 strain and uses thereof, wherein the Lactobacillus acidophilus KBL409 (deposit number KCTC 13518BP) strain according to the present invention reduces inflammation of the kidney, reduce the concentration of uremic toxins such as blood urea nitrogen, creatinine and p-cresol to protect the kidney, and thus may be usefully utilized for prophylactic and therapeutic applications of renal diseases including improving renal function and chronic renal failure.
-
公开(公告)号:US20220175858A1
公开(公告)日:2022-06-09
申请号:US17673488
申请日:2022-02-16
申请人: KoBioLabs, Inc.
发明人: Woo Ri Ko , June Chul Lee , Hyo In Park , Tae Wook Nam , Gwang Pyo Ko , Woon Ki Kim , Dae Hee Han , In Su Kim , Jin Woo Lee , Hye Jin Kim
IPC分类号: A61K35/747 , A23L33/135 , A61K8/02
摘要: A strain of Lactobacillus gasseri KBL697 and the use thereof are described. The strain of Lactobacillus gasseri KBL697 (Accession No. KCTC 13520BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects and a therapeutic effect for intestinal diseases such as irritable bowel syndrome and colitis. Thus, the single strain alone can achieve all the purposes of alleviating allergic diseases and inflammatory diseases and improving intestinal health, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.
-
公开(公告)号:US20230190829A1
公开(公告)日:2023-06-22
申请号:US18050091
申请日:2022-10-27
申请人: KoBioLabs, Inc.
发明人: Gwangpyo KO , Boram SEO , Woon Ki KIM , Kyungchan JEON
IPC分类号: A61K35/741 , A23L33/135 , A61K39/02
CPC分类号: A61K35/741 , A23L33/135 , A61K39/0208 , A61K2035/115
摘要: The present invention relates to a microorganism which can act as a biomarker of alcoholic fatty liver disease, and relates to a pharmaceutical composition for preventing or treating alcoholic fatty liver disease, a food composition for preventing or improving alcoholic fatty liver disease, or a probiotics composition for preventing or improving alcoholic fatty liver disease, comprising the strain as an active ingredient.
-
公开(公告)号:US11633439B2
公开(公告)日:2023-04-25
申请号:US17448620
申请日:2021-09-23
申请人: KoBioLabs, Inc.
发明人: Woo Ri Ko , June Chul Lee , Tae-Wook Nam , Gwang Pyo Ko , Hyun Ju You , So Yon Yoon , Seok Cheon Song
IPC分类号: A61K35/747 , A23L33/135 , A61P11/06 , A61P37/08 , A61P31/10 , A61K8/99
摘要: A strain of Lactobacillus crispatus KBL693 and the use thereof are disclosed. The strain of Lactobacillus crispatus KBL693 (Accession No. KCTC 13519BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects. Thus, the single strain alone can achieve all the purposes of alleviating atopic dermatitis and other allergic diseases and improving inflammatory diseases and autoimmune diseases, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.
-
-
-
-
-
-
-
-
-